Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

HIV vaccine research: the way forward.

Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, Greene WC.

Science. 2008 Jul 25;321(5888):530-2. doi: 10.1126/science.1161000.

PMID:
18653883
2.

Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.

Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC.

Nat Med. 2008 Jun;14(6):617-21. doi: 10.1038/nm.f.1759.

3.

25 years of HIV.

Fauci AS.

Nature. 2008 May 15;453(7193):289-90. doi: 10.1038/453289a. No abstract available.

PMID:
18480799
4.

Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E; Merck V520-016 Study Group..

Clin Infect Dis. 2008 Jun 1;46(11):1769-81. doi: 10.1086/587993.

6.

Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.

Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, Lemckert AA, Carville A, Mansfield KG, Havenga MJ, Goudsmit J, Barouch DH.

J Virol. 2008 May;82(10):4844-52. doi: 10.1128/JVI.02616-07.

7.

T-cell quality in memory and protection: implications for vaccine design.

Seder RA, Darrah PA, Roederer M.

Nat Rev Immunol. 2008 Apr;8(4):247-58. doi: 10.1038/nri2274. Review. Erratum in: Nat Rev Immunol. 2008 Jun;8(6):486.

PMID:
18323851
8.

A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.

Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3739-44. doi: 10.1073/pnas.0800255105.

9.

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl JP, Esteban M, Heeney J, Frachette MJ, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G.

J Exp Med. 2008 Jan 21;205(1):63-77. doi: 10.1084/jem.20071331.

10.

HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.

Sun ZY, Oh KJ, Kim M, Yu J, Brusic V, Song L, Qiao Z, Wang JH, Wagner G, Reinherz EL.

Immunity. 2008 Jan;28(1):52-63. doi: 10.1016/j.immuni.2007.11.018.

11.

Antibody-based HIV-1 vaccines: recent developments and future directions.

Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J; Working Group convened by the Global HIV Vaccine Enterprise..

PLoS Med. 2007 Dec;4(12):e348. No abstract available.

12.

Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, Wu X, Shaw GM, Connors M, Wyatt RT, Mascola JR.

Nat Med. 2007 Sep;13(9):1032-4.

13.

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major.

Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA.

Nat Med. 2007 Jul;13(7):843-50.

PMID:
17558415
14.

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses.

Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak DR, Asher TE, Douek DC, Harari A, Pantaleo G, Bailer R, Graham BS, Roederer M, Koup RA.

J Exp Med. 2007 Jun 11;204(6):1405-16.

15.

Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.

Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, Martin JE, Rucker S, Andrews CA, Gomez PL, Mascola JR, Nabel GJ, Graham BS; VRC 007 Study Team..

Vaccine. 2007 May 16;25(20):4085-92.

PMID:
17391815
16.

Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques.

Chong SY, Egan MA, Kutzler MA, Megati S, Masood A, Roopchard V, Garcia-Hand D, Montefiori DC, Quiroz J, Rosati M, Schadeck EB, Boyer JD, Pavlakis GN, Weiner DB, Sidhu M, Eldridge JH, Israel ZR.

Vaccine. 2007 Jun 21;25(26):4967-82.

PMID:
17335943
17.

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.

Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH.

J Virol. 2007 May;81(9):4654-63.

18.

Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques.

Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, Roopchand V, Garcia-Hand D, Abdullah R, Braun R, Montefiori DC, Rosati M, Felber BK, Pavlakis GN, Mathiesen I, Israel ZR, Eldridge JH, Egan MA.

J Virol. 2007 May;81(10):5257-69.

19.

Structural definition of a conserved neutralization epitope on HIV-1 gp120.

Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD.

Nature. 2007 Feb 15;445(7129):732-7.

20.

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD, Hahn BH, Korber BT.

Nat Med. 2007 Jan;13(1):100-6.

PMID:
17187074
Items per page

Supplemental Content

Support Center